R3i Foundation

The Residual Risk Reduction Initiative (R3i) is a global, multidisciplinary non-profit organization focused on reducing the remaining risk of macrovascular and microvascular complications. It addresses patients whose vascular risk persists whether or not they have reached treatment goals under current standards of care. R3i supports healthcare professionals with evidence-based information intended to inform clinical decisions and improve patient outcomes.

Through its website, the initiative offers educational and reference materials, including booklets, slidekits, webinars, talks, video series, editorials, and publications on residual vascular risk. Topics include diabetic retinopathy, metabolic dysfunction-associated steatohepatitis, PCSK9-targeted therapies, triglyceride-rich lipoproteins, and approaches to cardiovascular risk in diabetes and chronic kidney disease. R3i also shares relevant research and clinical trial insights, and provides information about its events and the Jean-Charles Fruchart Prize. Visitors can subscribe to its newsletter and access downloadable educational resources. Based in Basel, Switzerland, R3i presents its content for educational purposes; it is not a substitute for advice from a qualified health professional.